Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-mutant Non-small Cell Lung Cancer”

195 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 195 results

Testing effectiveness (Phase 2)UnknownNCT02725918
What this trial is testing

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Who this might be right for
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 150
Not applicableLooking for participantsNCT07028489
What this trial is testing

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
N-Power Medicine 130
Early research (Phase 1)Looking for participantsNCT04780568
What this trial is testing

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
Ohio State University Comprehensive Cancer Center 24
Large-scale testing (Phase 3)UnknownNCT04028778
What this trial is testing

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

Who this might be right for
Lung Cancer, Nonsmall Cell
Sun Yat-sen University 310
Not applicableStudy completedNCT07267247
What this trial is testing

Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)Drug-Related Side Effects and Adverse Reactions (MeSH Term)Egfr Tyrosine Kinase Inhibitor+1 more
Taichung Veterans General Hospital 100
Post-approval studies (Phase 4)Ended earlyNCT02299765
What this trial is testing

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGFR Activating Mutation
Sichuan University 61
Testing effectiveness (Phase 2)Looking for participantsNCT06924398
What this trial is testing

Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）

Who this might be right for
Lung Cancer (NSCLC)
Sun Yat-sen University 32
Testing effectiveness (Phase 2)Ended earlyNCT02630186
What this trial is testing

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 3
Testing effectiveness (Phase 2)UnknownNCT05987826
What this trial is testing

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Shanghai Zhongshan Hospital 40
Testing effectiveness (Phase 2)WithdrawnNCT02297425
What this trial is testing

Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Who this might be right for
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer
Testing effectiveness (Phase 2)UnknownNCT02960607
What this trial is testing

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Chinese Academy of Medical Sciences 25
Testing effectiveness (Phase 2)WithdrawnNCT06227897
What this trial is testing

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

Who this might be right for
Lung Cancer
Sun Yat-sen University
Testing effectiveness (Phase 2)Looking for participantsNCT06186076
What this trial is testing

Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

Who this might be right for
Carcinoma, Non-Small-Cell LungEGFR Mutant Advanced Non-Small Cell Lung Cancer
Therapex Co., Ltd 115
Large-scale testing (Phase 3)UnknownNCT04500704
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 166
Testing effectiveness (Phase 2)Active Not RecruitingNCT05601973
What this trial is testing

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Who this might be right for
Non Small Cell Lung Cancer
ETOP IBCSG Partners Foundation 60
Testing effectiveness (Phase 2)WithdrawnNCT02705339
What this trial is testing

Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell LungNon-Small Cell Lung CancerNonsmall Cell Lung Cancer
Washington University School of Medicine
Testing effectiveness (Phase 2)Ended earlyNCT03091491
What this trial is testing

Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
National Cancer Centre, Singapore 31
Testing effectiveness (Phase 2)Ended earlyNCT04971187
What this trial is testing

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+7 more
M.D. Anderson Cancer Center 3
Testing effectiveness (Phase 2)UnknownNCT04517526
What this trial is testing

Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study

Who this might be right for
Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT
Shanghai Cancer Hospital, China 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT05017025
What this trial is testing

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+6 more
M.D. Anderson Cancer Center 32
Load More Results